Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Leiomyoma 4Menorrhagia 2

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × linzagolix × Clear all
NCT05445167 2025-11-25

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain

Kissei Pharmaceutical Co., Ltd.

Phase 3 Completed
89 enrolled

Leiomyoma

NCT05440383 2025-03-14

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia

Kissei Pharmaceutical Co., Ltd.

Phase 3 Completed
287 enrolled

Leiomyoma

NCT03070899 2021-06-09

PRIMROSE 1

ObsEva SA

Phase 3 Completed
526 enrolled

Leiomyoma, Menorrhagia

NCT03070951 2021-03-05

PRIMROSE 2

ObsEva SA

Phase 3 Completed
511 enrolled

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡